The race in peptide medicines is moving beyond drug discovery and into manufacturing.
On August 31, Samsung Biologics published the formal tender offer prospectus for Switzerland-based PolyPeptide Group. The offer is CHF 44.31 per share in cash, implying an equity value of roughly CHF 1.46 billion. The offer period is scheduled to run from September 15 to October 12. PolyPeptide’s largest individual shareholder, holding about 55.65% of shares, has committed to tender, while the company’s independent board members have recommended the offer.
The significance lies less in the headline value than in the assets Samsung is seeking to acquire: a specialised, international peptide API CDMO network.
PolyPeptide develops and manufactures peptide-based active pharmaceutical ingredients across sites in Europe, the United States and India. Demand for these capabilities is rising sharply as peptide medicines gain ground in obesity, diabetes, oncology, metabolic disease and other therapeutic areas. GLP-1 drugs are the most visible driver, but the manufacturing challenge extends well beyond them.
For drug developers, access to reliable, compliant and scalable peptide API capacity has become a strategic issue. A promising molecule still needs process expertise, qualified equipment, regulatory systems and a supply network capable of moving from development batches to commercial volumes.
Samsung Biologics has built its reputation around antibodies, ADCs and mRNA-related capabilities. Bringing PolyPeptide into the group would add a new modality and a functioning global manufacturing footprint. It would also create a larger supplier for clients looking to consolidate development and commercial production across several drug platforms.
The transaction has implications for Chinese API and CDMO companies as well. Global customers are increasingly weighing not only cost, but also geography, capacity security, technology transfer and regulatory reach. If Samsung completes the acquisition, it will have peptide manufacturing nodes across Europe, the United States and India—raising the bar for competitors seeking global mandates.
The deal is not yet closed. But its direction is unmistakable: the GLP-1 boom is becoming a contest for peptide manufacturing capacity, process know-how and global supply-chain control.
